UNSPSC 51171937: Ebrotidine

This classification denotes a histamine-2 receptor antagonist with the molecular formula C14H17BrN6O2S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TMZ3IBW2OW, chemically known as benzenesulfonamide, n-(((2-(((2-((aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)ethyl)amino)methylene)-4-bromo-, (e)- but generally known as ebrotidine, which bears US NIH Compound Identifier 65869. European Medicines Agency schedules Ebrotidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06438MIG.

UNSPSC 51171937 Ebrotidine, a Commodity code, represents a narrow pharmaceutical product line with minimal documented state and local procurement activity. The recent opportunities tagged under this code do not reflect direct purchasing of ebrotidine itself; instead, they span specimen collection and drug testing services (Collin County Community Supervision and Corrections Department), exploratory market research into direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), and multi-source generic pharmaceutical and OTC product procurement through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). The mismatch between the code's specific pharmaceutical designation and the scope of these opportunities suggests either tagging inconsistency or that ebrotidine procurement, if occurring, is bundled within broader pharmaceutical or testing-services categories rather than solicited as a standalone commodity.

Collin County Community Supervision and Corrections Department posted RFP 2026-327 on July 9, 2026, due July 23, 2026, for offender specimen collection and drug testing services covering two collection sites in Plano and McKinney with annual testing volume of approximately 25,031 tests, including five-panel and six-panel screens and confirmatory analysis; the estimated contract value is $600,000 over two years with three optional one-year renewals. The Texas Health and Human Services Commission issued RFI No. HHS0017013 on March 27, 2026 (response deadline April 3, 2026) seeking vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Department of Administration, administering the Minnesota Multistate Cooperative Purchasing Alliance, posted RFP S1070000015802 on January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities including Oregon, with awarded vendors effective July 1, 2026. Activity is concentrated in Texas and Minnesota, with no other states or jurisdictions represented in recent opportunities.